Search Results - "Shupenina, E. Yu"

Obesity in metabolic syndrome, as well as kidney dysfunction by Sadulaeva, I A, Vasyuk, Yu A, Trofimenko, O S, Yushchuk, E N, Ivanova, S V, Shupenina, E Yu, Nesterova, E A

“…The presence of metabolic syndrome (MS) in a patient allows him to be assigned to a group at high risk for atherosclerosis, cardiovascular events, coronary…”
Get full text

Atrial fibrillation in a patient with lung cancer: a case report by Shupenina, E. Yu, Vyzhigin, D. I., Gaganov, L. E., Novosel, E. O.

“…Introduction. Cancer remains one of the most common causes of death in the world, second only to cardiovascular diseases. The use of novel chemotherapeutic and…”
Get full text

Guidance letter for cardiologists of oncology institutions on the prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology by Vasyuk, Yu. A., Gendlin, G. E., Emelina, E. I., Nikitin, I. G., Potievskaya, V. I., Shupenina, E. Yu

Get full text

Guidance letter for cardiologists and primary care physicians on primary prevention of cardiovascular complications of anticancer therapy. Interdisciplinary Council of Cardio-Oncology, Russian Society of Cardiology by Vasyuk, Yu. A., Gendlin, G. E., Emelina, E. I., Nikitin, I. G., Potievskaya, V. I., Shupenina, E. Yu

Get full text

Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy by Vasyuk, Yu. A., Gendlin, G. E., Emelina, E. I., Shupenina, E. Yu, Ballyuzek, M. F., Barinova, I. V., Vitsenya, M. V., Davydkin, I. L., Dundua, D. P., Duplyakov, D. V., Zateishchikov, D. A., Zolotovskaya, I. A., Konradi, A. O., Lopatin, Yu. M., Moiseeva, O. M., Nedogoda, S. V., Nedoshivin, A. O., Nikitin, I. G., Poltavskaya, M. G., Potievskaya, V. I., Repin, A. N., Sumin, А. N., Zotova, L. A., Tumyan, G. S., Shlyakhto, E. V., Khatkov, I. E., Yakushin, S. S., Belenkov, Yu. N.

Get full text

Novel algorithms for diagnosing heart failure with preserved ejection fraction in patients with hypertension and obesity by Vasyuk, Yu. A., Shupenina, E. Yu, Namazova, G. A., Dubrovskaya, T. I.

“…Heart failure with preserved ejection fraction (HFpEF) is a complex clinical syndrome associated with frequent hospitalizations, high mortality rates, and an…”
Get full text

Atrial Fibrillation in Cancer Patients: Who is at Risk? by Vasyuk, Yu. A., Shupenina, E. Yu, Vyzhigin, D. A., Novosel, E. O., Gallinger, K. V.

“…Cancer is the second leading cause of mortality in the world, second only to cardiovascular diseases. Simultaneously cancer mortality has been steadily…”
Get full text

Modern fixed combinations of antihypertensive drugs in the treatment of arterial hypertension and obesity: can this comorbid pathology be effectively controlled? by Vasyuk, Yu. A., Shupenina, E. Yu, Yuschuk, E. N., Namazova, G. A.

“…Aim. To assess the effect of azilsartan/chlortalidone and irbesartan/hydrochlorothiazide fixed combinations on office, daily peripheral and central blood…”
Get full text

INFLUENCE OF COMBINATION ANTIHYPERTENSIVE THERAPY ON AORTA STIFFNESS PARAMETERS AND CENTRAL ARTERIAL PRESSURE IN HYPERTENSIVES WITH OBESITY by E. Yu. Shupenina, Yu. A. Vasyuk, E. A. Nesterova, S. V. Ivanova

“…Aim. In the study we evaluated the influence of antihypertension therapy on 24-hour central BP and parameters of aorta stiffness in hypertensive patients with…”
Get full text

COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE: IS IT POSSIBLE TO FIGHT SYSTEMIC HYPERTENSION AND OBESITY TOGETHER? by Vasyuk, Yu. A., Shupenina, E. Yu, Nesterova, E. A., Golubkova, E. I., Nesvetov, V. V.

“…Arterial hypertension (AH) and obesity are the main risk factors of chronic noncommunicable diseases. Adipous tissue is not only a depot for…”
Get full text

BRAIN NATRIURETIC PEPTIDE AS BIOCHEMICAL MARKER FOR STRUCTURAL AND FUNCTIONAL HEART DISORDERS IN ARTERIAL HYPERTENSION by S. V. Ivanova, Yu. A. Vasyuk, E. Yu. Shupenina, P. V. Krikunov, I. A. Sadulaeva

“…Aim. Assessment of structural and functional condition of the left and right heart chambers related to the level of NT-proBNP and clinical signs of CHD in AH…”
Get full text

A COMPARISON OF THE MAIN ANTIHYPERTENSIVE DRUGS FROM THE VIEWPOINT OF AORTIC STIFFNESS MODIFICATION IN ARTERIAL HYPERTENSION by Shupenina, E. Yu, Vasyuk, Yu. A., Khadzegova, A. B., Ivanova, S. V., Nadina, E. V., Khuchinaeva, A. M.

“…A plenty of trials confirm the importance of aortic wall stiffness evaluation during estimation of the cardiovascular risk and the need for novel drugs…”
Get full text

AORTIC STIFFNESS ASSESSMENT IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY by Shupenina, E. Yu, Yushchuk, E. N., Khadzegova, A. B., Ivanova, S. V., Sadulaeva, I. A., Nadina, E. V., Khuchinaeva, A. M., Vasyuk, Yu. A.

“…Cardiovascular disease (CVD) remains the leading cause of death in most developed countries. Morphological and functional status of large arteries plays an…”
Get full text

Characteristics of arterial hypertension clinical course in patients with obesity and anxiety-depressive disorders by Vasyuk, Y A, Dovzhenko, T V, Dubrovskaya, T I, Nesterova, E A, Shupenina, E Y

“…This article covers an important subject clinical course of arterial hypertension in patients with metabolic abnormalities with obesity and anxiety-depressive…”
Get full text